Skip to main content

Atrial Fibrillation - Anticoagulation Therapy

CBE ID
0624
1.4 Project
National Voluntary Consensus Standards For Clinically Enriched Administrative Data
Endorsed
Endorsement Status
Endorsement Removed
1.1 New or Maintenance
Maintenance
E&M Cycle
Full Year 2009
Is Under Review
No
1.3 Measure Description

Percentage of adult patients aged 25 and older with atrial fibrillation and major stroke risk factors who are on anticoagulation therapy.

    • 1.14 Numerator

      Patients with evidence of anticoagulation therapy.

    • 1.15 Denominator

      All patients with Atrial Fibrillation and one of the following:

      1. Age greater than or equal to 25 with prior stroke, mitral stenosis or mitral valve replacement
      2. Age greater than or equal to 75 and 1 of the following: diabetes, hypertension or CHF
      3. Age less than 75 and 2 of the following: diabetes, hypertension or CHF

    • Exclusions

      Contraindications to warfarin, including:
      • Esophageal varices with bleed
      • Aortic dissection
      • Intracerebral hemorrhage
      • Blood transfusion(RBC or platelets)
      • Severe brain injury
      • Dementia
      • Alcohol use/abuse
      • Falls
      • Fracture
      • Hemorrhage contraindications and procedures
      • Adverse effects fromcoumadin
      • Abnormal gait/incoordination
      • Neuro and eye surgery
      • Gastritis with Current fill of Proton pump inhibitors
      • Thrombocytopenia
      • Hematocrit lab value < 25
      • Pregnancy
      • Patient or provider feedback indicating patient has allergy, intolerance, or contraindication to the drug anytime in the past



      • General exclusions:
      Terminal illness anytime in the past
      hospice in the past 12 months

    • Most Recent Endorsement Activity
      Measure Retired and Endorsement Removed National Voluntary Consensus Standards For Clinically Enriched Administrative Data
      Initial Endorsement
      Last Updated
      Removal Date